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Angiogenesis inhibitors remain under active investigation in the treatment of lung cancer. At the 12th annual Targeted 
Therapies of the Treatment of Lung Cancer meeting in Santa 
Monica, Dr. John Heymach reviewed several of the proangio-
genic receptor tyrosine kinase pathways that are considered to 
play a significant role in the pathogenesis of lung cancer. His 
introduction was followed by eight presentations, discussing 
the latest developments of antiangiogenic agents being evalu-
ated in non–small-cell lung cancer (NSCLC).
Vascular endothelial growth factor (VEGF) is one of the 
key mediators of angiogenesis, but there are other important 
angiogenic factors, including fibroblast growth factor receptor, 
platelet-derived growth factor (PDGF), Notch/Delta-like ligand 
4 signaling, and Tie2/Angiopoietin signaling. Bevacizumab, a 
monoclonal antibody to VEGF, remains the one and only anti-
angiogenic agent approved for the treatment of lung cancer. 
There are efforts to evaluate a number of other angiogenesis 
inhibitors in NSCLC and additional data are awaited from 
ongoing studies in order to establish the exact role of antian-
giogenic agents in the NSCLC treatment paradigm.
SUMMARY OF PRESENTATIONS
Dr. Michael O’Reilley reviewed the current status of bio-
markers for antiangiogenic therapy. Both predictive and prog-
nostic angiogenesis-related biomarkers are being explored in 
patients with lung cancer. Increased lung tumor microvessel den-
sity has been associated with poor prognosis in patients with sur-
gically resected lung cancer.1 In addition, an analysis of Eastern 
Cooperative Oncology Group 4599 showed that low levels of 
E-selectin and high plasma VEGF levels were independently pre-
dictive of response to bevacizumab, whereas low baseline intra-
cellular adhesion molecule levels correlated with improvement in 
progression-free survival (PFS).2 More recently, there have been 
studies investigating the role of circulating endothelial progenitors 
as well as plasma cytokine and angiogenic factors in predicting 
response to various anti-VEGF treatments. Identifying biomark-
ers for antiangiogenic therapies remains an important goal and 
an area of active research as we attempt to customize therapy for 
individual patients in this era of personalized medicine.
Cediranib (AZD 2171) is a highly potent small-molecule 
tyrosine kinase inhibitor of VEGFR-1/2, platelet-derived growth 
factor receptor-beta, and c-kit. Dr. Frances Shepherd provided an 
overview on the clinical development of cediranib in NSCLC. In 
the phase I/II randomized, double-blind trial of carboplatin and 
paclitaxel with either daily oral cediranib or placebo in advanced 
non-small-cell lung cancer (BR.24) patients with advanced 
NSCLC were randomized to receive carboplatin/paclitaxel 
± cediranib at a dose of 30 mg daily as frontline treatment. An 
interim analysis after accrual of 150 patients revealed that patients 
receiving cediranib had an improvement in overall response rate 
(ORR; 38% versus 16%) and PFS (hazard ratio [HR], 0.77, CI, 
0.56–1.08) compared with those patients receiving placebo. 
However, cediranib at a dose of 30 mg daily was associated with 
excessive toxicities including febrile neutropenia, hypertension, 
and gastrointestinal effects.3 On multivariate analyses, these tox-
icities were found to be more pronounced in patients with weight 
loss of more than 5% and hypoalbuminemia. The subsequent 
BR.29 trial used a reduced dose of cediranib at 20 mg daily in 
combination with carboplatin/paclitaxel. The results of a planned 
interim safety analysis on the first 260 patients was presented 
at American Society of Clinical Oncology 2012, indicating an 
increase in response rate and toxicity, but not PFS or overall sur-
vival (OS), with the addition of a lower dose of cediranib to car-
boplatin/paclitaxel.4 The study was closed to accrual in May 2011 
because cediranib did not meet prespecified PFS criteria.
Dr. Heather Wakelee reviewed the data regarding BIBF 
1120, an inhibitor of VEGFR-1/2/3, PDGFR, and fibroblast 
growth factor receptor. Phase I studies indicated a maximum 
tolerated dose of 200 mg twice daily with a dose-limiting toxic-
ity of transaminitis and with minimal hypertension seen.5 In lung 
 cancer, two phase III trials in the second-line setting have now 
completed accrual and results are forthcoming for their evaluation 
of BIBF 1120 in combination with docetaxel (LUME Lung 1) 
and in combination with pemetrexed (LUME Lung 2).
Pazopanib is an oral angiogenesis inhibitor that targets 
VEGFR, PDGFR, and c-kit, and has been approved for treat-
ment of metastatic renal cell carcinoma. Dr. George Simon 
summarized the results of a phase I study in which pazo-
panib 800 mg/m2 plus paclitaxel 150 mg/m2 was determined 
to be the maximum tolerated regimen, and the combination 
demonstrated antitumor activity in patients with melanoma 
and NSCLC.6 A subsequent phase II study has recently com-
pleted accrual, comparing pazopanib or pemetrexed as main-
tenance therapy in nonprogressing patients with advanced 
nonsquamous NSCLC who had received induction cispla-
tin/pemetrexed or carboplatin/pemetrexed. There are several 
other ongoing studies evaluating pazopanib in patients with 
advanced NSCLC, and results are awaited.
Dr. Ross Camidge updated data regarding ramu-
cirumab, a monoclonal antibody against VEGFR-2. In a 
single-arm phase II study that evaluated ramucirumab in 
combination with carboplatin/paclitaxel, ramucirumab was 
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associated with an ORR of 59% and disease-control rate of 
97%.7 There is an ongoing phase II randomized trial evalu-
ating patients with metastatic NSCLC, including all histolo-
gies, in the frontline setting. According to this trial, patients 
with nonsquamous histology receive platinum/pemetrexed ± 
ramucirumab × 4–6 cycles, followed by maintenance peme-
trexed in both arms; patients with squamous histology receive 
platinum/gemcitabine ± ramucirumab × 4–6 cycles, followed 
by maintenance ramucirumab in the ramucirumab arm. The 
nonsquamous enrollment has been completed and the squa-
mous enrollment in ongoing. In addition, a phase III study is 
also underway, enrolling patients with metastatic NSCLC who 
have progressed after receiving frontline platinum-based ther-
apy, randomizing them to receive docetaxel ± ramucirumab.
MEGF 0444A is a humanized monoclonal antibody against 
epidermal growth factor-like domain multiple 7, an extracellular 
matrix protein that supports endothelial cell survival. Dr. David 
Spigel reviewed data from the initial phase I studies, in which the 
combination of MEGF 0444A and bevacizumab was found to 
exhibit antitumor activity and was safe with no significant exacer-
bation of bevacizumab-related toxicities. In the ongoing phase II 
Study Evaluating the Safety and Efficacy of MEGF0444A in 
Combination With Carboplatin, Paclitaxel and Bevacizumab in 
Patients With Advanced or Recurrent Non-Squamous Non-Small 
Cell Lung Cancer Who Have Not Received Prior Chemotherapy 
for Advanced Disease (NILE), patients with advanced or recur-
rent nonsquamous NSCLC who have not received prior che-
motherapy are randomized to receive carboplatin/paclitaxel/
bevacizumab ± MEGF 0444A. To date, there are no significant 
adverse events, and a formal interim safety analysis is pending.
Vascular disrupting agents (VDAs) act upon established 
blood vessels of actively proliferating tumors, leading to arrest 
of blood flow and tumor necrosis. Dr. Primo Lara provided 
an update on a number of VDAs being evaluated in NSCLC. 
ASA-404 was a VDA that yielded disappointing results in 
NSCLC, with no improvement in overall survival (OS) seen 
in the phase III ASA404 or Placebo in Combination With 
Paclitaxel and Carboplatin as First-Line Treatment for Stage 
IIIb/IV Non-Small Cell Lung Cancer (ATTRACT-1) study of 
carboplatin/paclitaxel ± ASA-404, leading to discontinuation 
of further development of this agent.8 VDAs that remain in 
current clinical development in NSCLC include fosbretabulin 
and bavituxumab. In the phase II Fosbretabulin in Advanced 
Lung Oncology (FALCON) trial, chemotherapy-naive patients 
with nonsquamous metastatic disease were randomized to 
receive carboplatin/paclitaxel/bevacizumab ± fosbretabulin. 
Preliminary results indicated that the addition of fosbretabulin 
was associated with an ORR of 56%, compared with 36% in 
those patients receiving carboplatin/paclitaxel/bevacizumab 
alone. Moreover, in patients with an aggregate tumor burden 
of more than 10 cm, OS was improved with the addition of fos-
bretabulin (14. 2 months versus 11.0 months, HR: 0.67, 95% 
CI, 0.26–0.7).9 Bavituxumab is a VDA monoclonal antibody, 
which targets the phosphatidylserine/beta-2 glycoprotein 1 
complex. In a phase II study, bavituxumab was combined with 
carboplatin/paclitaxel and was found to have an ORR of 43%, 
a median PFS of 6.1 months, and a median OS of 12.4 months 
([Press release] retrieved from http://ir.peregrineinc.com/
releasedetail.cfm?ReleaseID=655805). There are randomized 
phase II studies underway evaluating bavituxumab in both the 
first- and second-line settings in NSCLC.
Ombrabulin is another novel VDA that is an analogue of 
combretastatin A4 and a tubulin-binding agent, causing shut-
down of tumor vasculature by attacking endothelial cells. Dr. 
Barry Childs discussed the early data suggesting synergism 
between ombrabulin and platinum agents. On the basis of these 
encouraging results, there are ongoing trials of ombrabulin 
in solid tumors, including NSCLC. In the multinational, pla-
cebo-controlled phase II Trial of Ombrabulin (AVE8062) in 
Combination With Taxane and Platinum in Patients With Non-
small Cell Lung Cancer (DISRUPT), patients with metastatic 
NSCLC are randomized to receive frontline treatment with tax-
ane and platinum with or without ombrabulin. The primary out-
come of the trial is PFS and initial data are anticipated in 2013.
FUTURE DIRECTIONS
Antiangiogenic therapies have demonstrated promise in 
the treatment of NSCLC. Bevacizumab remains the only Food 
and Drug Administration approved antiangiogenic agent in lung 
cancer, although data are awaited from several ongoing stud-
ies involving other antiangiogenic agents. The identification 
and validation of biomarkers is under active investigation and 
remains a crucial goal to help identify upfront those patients 
who are most likely to benefit from angiogenesis inhibition.
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